Lexaria Bioscience Corp. (NASDAQ:LEXX – Free Report) – Analysts at Zacks Research lowered their FY2026 EPS estimates for shares of Lexaria Bioscience in a research note issued on Friday, July 17th. Zacks Research analyst J. Vandermosten now expects that the company will earn ($0.27) per share for the year, down from their prior estimate of ($0.26). The consensus estimate for Lexaria Bioscience’s current full-year earnings is ($0.26) per share.
Separately, Weiss Ratings raised shares of Lexaria Bioscience from a “sell (e+)” rating to a “sell (d-)” rating in a report on Monday, July 13th. One equities research analyst has rated the stock with a Buy rating and one has assigned a Sell rating to the company. According to MarketBeat, the stock has a consensus rating of “Hold” and an average price target of $1.50.
Lexaria Bioscience Price Performance
Shares of LEXX stock opened at $0.56 on Thursday. Lexaria Bioscience has a one year low of $0.46 and a one year high of $1.55. The stock’s fifty day simple moving average is $0.60 and its 200 day simple moving average is $0.71. The firm has a market cap of $13.87 million, a price-to-earnings ratio of -1.65 and a beta of 0.34.
Lexaria Bioscience (NASDAQ:LEXX – Get Free Report) last issued its earnings results on Monday, July 13th. The company reported ($0.08) earnings per share for the quarter, missing the consensus estimate of ($0.06) by ($0.02).
Institutional Inflows and Outflows
Hedge funds have recently modified their holdings of the business. Byrne Asset Management LLC boosted its stake in Lexaria Bioscience by 236.8% in the fourth quarter. Byrne Asset Management LLC now owns 105,500 shares of the company’s stock valued at $65,000 after acquiring an additional 74,180 shares during the last quarter. Geode Capital Management LLC lifted its holdings in shares of Lexaria Bioscience by 25.7% during the 4th quarter. Geode Capital Management LLC now owns 219,718 shares of the company’s stock valued at $136,000 after purchasing an additional 44,939 shares in the last quarter. Finally, Virtu Financial LLC bought a new position in Lexaria Bioscience in the third quarter valued at approximately $28,000. Institutional investors own 13.06% of the company’s stock.
About Lexaria Bioscience
Lexaria Bioscience Corp. (NASDAQ: LEXX) is a biotech company specializing in the development and commercialization of proprietary drug delivery platforms. The company’s flagship technology, DehydraTECH, is designed to improve the oral bioavailability, onset time and overall efficiency of active molecules such as cannabinoids, nicotine and other lipophilic compounds. Lexaria’s platform seeks to address absorption challenges commonly associated with oral delivery by enhancing the rate and extent at which compounds enter the bloodstream.
Founded in 2014 and headquartered in Kelowna, British Columbia, Lexaria operates in the pharmaceutical, nutraceutical and consumer product markets.
See Also
- Five stocks we like better than Lexaria Bioscience
- Could Truth API Become Trump Media’s First Meaningful Revenue Driver?
- Small Caps Are Crushing the S&P 500—3 Stocks Still Worth Buying
- Moog Is More Than a Missile Maker, and Wall Street Is Noticing
- A Boring Dividend Growth Strategy Becomes a Solid Defensive Play
Receive News & Ratings for Lexaria Bioscience Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Lexaria Bioscience and related companies with MarketBeat.com's FREE daily email newsletter.
